Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)

About Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Precision medicine involves the analysis of an individual’s tumor biology, to optimally design patient treatment plans. The discovery of biomarkers predictive of drug-response will allow assignment of patients to therapies most likely to benefit them and avoid unnecessary treatments and morbidities.
  • Dr. Armstrong and team will identify potential predictive biomarkers of response and resistance to abiraterone, enzalutamide, and taxane-chemotherapy in mCRPC patients.
  • Potential predictive biomarkers will be determined by assessing the biology and genomic features of circulating tumor cells and circulating tumor DNA obtained from successive blood samples drawn from patients undergoing therapy.
  • The androgen receptor (AR) is the primary driver of prostate cancer growth and survival and is the main molecular target today for the treatment of prostate cancer. Shorter variant forms of AR (AR-Vs) can be highly active and drive tumor growth even in the presence of current AR-targeting agents. A major focus of this project will be to examine if the presence of AR-Vs can predict drug response and resistance.
  • These studies will contribute to the development of a precision medicine approach for CRPC patients.

What this means for patients: The future of oncology practice involves the genetic analysis of an individual’s tumor to select therapies most likely to benefit them. This project will determine predictive biomarkers of response and drug resistance to the major therapies available for mCRPC patients — abiraterone, enzalutamide, and taxane-chemotherapy and will inform precision medicine strategies for prostate cancer patients.

Principal Investigator:

Andrew Armstrong, MD, MSc (Duke University)

Co-investigators:

David Nanus, MD (Weill Medical College of Cornell University), Paraskevi Giannakakou, PhD (Weill Medical College of Cornell University), Emmanuel Antonarakis, MD (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center), Jun Luo, PhD (Johns Hopkins University), Simon Gregory, PhD (Duke University), Susan Halabi, PhD (Duke University), Scott Tagawa, MD, MSc (Weill Medical College of Cornell University), Daniel George, MD (Duke University), Himisha Beltran, MD (Weill Medical College of Cornell University), Jason Somarelli, PhD (Duke University), Giuseppe Galletti, MD, PhD (Weill Medical College of Cornell University), Ryan Dittamore, PhD (Epic Sciences).